Luspatercept as first treatment for low-risk myelodysplastic syndromes
Treatments studied
Part of Blood & lymphatic clinical trials.
This trial tests a drug called luspatercept (Reblozyl) as the first treatment for people with a bone marrow disorder that causes low blood counts and requires regular blood transfusions. The drug may help reduce the need for transfusions by improving red blood cell production.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have a diagnosis of myelodysplastic neoplasms (a bone marrow disorder) that is classified as very low, low, or intermediate risk.
- You must have needed at least 2 red blood cell transfusions in the 8 weeks before starting treatment.
- Your doctor has decided that luspatercept is the right first treatment for you.
- You cannot be in another interventional clinical trial or have another cancer that requires treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 trial studies luspatercept to improve anemia (low red blood cells) in people with MDS that has a del5q change. It also checks safety, especially for people who need red blood cell transfusions and have not benefited from prior standard treatments.
This Phase 1/2 study tests luspatercept combined with another approach in people with low-risk myelodysplastic syndrome (MDS) who are not responding to or cannot use ESA (a common anemia treatment). It may help improve anemia (low hemoglobin), reduce transfusions, and control the disease if you fit the specific criteria.
This trial tests a drug called luspatercept to see if it can improve red blood cell production in people with certain rare inherited anemias. If you have one of these anemias and have low hemoglobin, this study might help you reduce or avoid blood transfusions.
This study tests a drug called luspatercept, which helps the body make more red blood cells, in people with low-risk myelodysplastic syndromes (MDS) who have anemia. The goal is to see if it quickly improves blood counts, and you'll track your progress using a smartphone app.
This Phase 2 trial studies whether luspatercept can improve anemia in people with lower-risk myelodysplastic syndrome (MDS) who do not currently need red-blood-cell transfusions. It’s also looking to see if the benefit is similar whether or not you have ring sideroblasts.
This trial is testing whether a combination of two drugs, luspatercept and darbepoetin alfa, can help people with lower-risk myelodysplastic syndromes (MDS) who need frequent red blood cell transfusions. The goal is to see if the combination reduces their need for transfusions.
Hear when a new Myelodysplastic Neoplasms trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.